New England Research & Management Inc. Acquires Shares of 1,550 Natera, Inc. $NTRA

Key Points

• New England Research & Management Inc. acquired a stake in Natera, Inc., purchasing 1,550 shares valued at approximately $262,000 in the second quarter of the year.
• Analysts remain optimistic about Natera, with multiple firms giving buy ratings and target prices ranging from $183 to $210, collectively indicating a strong positive outlook.
• In recent insider trading, CFO Michael Burkes Brophy sold 3,045 shares, reflecting a 4.45% reduction in his ownership, while corporate insiders have collectively sold $8.46 million worth of shares in the last ninety days.

New England Research & Management Inc. acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,550 shares of the medical research company's stock, valued at approximately $262,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Natera by 788.3% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 7,995 shares of the medical research company's stock valued at $1,351,000 after purchasing an additional 7,095 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Natera during the 1st quarter valued at about $1,136,000. Swedbank AB boosted its holdings in shares of Natera by 48.8% during the 1st quarter. Swedbank AB now owns 45,135 shares of the medical research company's stock valued at $6,383,000 after purchasing an additional 14,809 shares during the last quarter. Strs Ohio bought a new position in shares of Natera in the 1st quarter valued at about $8,992,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Natera by 142.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company's stock valued at $155,000 after acquiring an additional 646 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on NTRA shares. Stephens reissued an "overweight" rating and issued a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Morgan Stanley restated an "overweight" rating and issued a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. Finally, Barclays restated an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to MarketBeat, Natera has an average rating of "Buy" and an average target price of $194.00.

Natera Trading Up 2.2%

Shares of NTRA stock opened at $172.16 on Tuesday. The company has a market capitalization of $23.63 billion, a PE ratio of -90.14 and a beta of 1.68. The firm has a fifty day simple moving average of $155.45 and a 200-day simple moving average of $154.23. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue was up 32.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other news, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the transaction, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,423 shares of company stock valued at $8,459,656. Corporate insiders own 5.63% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.